\n\nThe decision directly affects the popular GLP-1 agonist drugs, including the active ingredients in brands like Ozempic, Wegovy, and Mounjaro. \n\n\n\nThe WHO’s recommendation aims to pressure pharmaceutical giants to lower prices and encourage the production of affordable generic versions. This is particularly important for people in developing countries, where they are needed most.\n\n\n\nThis move underscores the severity of the global…